Abstract
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents, Immunological / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors*
-
CTLA-4 Antigen / antagonists & inhibitors*
-
Humans
-
Immunotherapy / methods*
-
Ipilimumab / therapeutic use
-
Neoplasms / therapy*
-
Nivolumab / therapeutic use
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
durvalumab
-
Nivolumab
-
atezolizumab
-
pembrolizumab